Loading...

Sareum Holdings plc

SAR.L•LSE
Healthcare
Biotechnology
£16.50
£-0.50(-2.94%)

Sareum Holdings plc (SAR.L) Company Profile & Overview

Explore Sareum Holdings plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Sareum Holdings plc (SAR.L) Company Profile & Overview

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

SectorHealthcare
IndustryBiotechnology
CEOStephen Barry Parker DPhil,

Contact Information

https://www.sareum.com
44 1223 497 700
Langford Arch, Cambridge, CB22 3FX

Company Facts

5 Employees
IPO DateOct 11, 2004
CountryGB
Actively Trading

Frequently Asked Questions

;